

39th International Conference on Screening for Lung Cancer 7th Conference on Research for Early Lung Cancer Treatment

October 16th & 17th, 2018



Hosted by

VASSAR BROTHERS MEDICAL CENTER

HEALTHQUEST

*The Marriott Pavilion Conference Center (Ecolab Auditorium)
Culinary Institute of America
1946 Campus Drive (Route 9), Hyde Park, NY 12538*

The mission of our conference is to understand and confront the issues surrounding early diagnosis and treatment of lung cancer and interstitial lung disease (ILD); and to expand the reach of practice-relevant research to medical and scientific communities nationally and abroad.

Tuesday, October 16th

- 8:30 *REGISTRATION & BUFFET BREAKFAST*
- 9:00 – 9:30 **Welcome.** *C. Connery, Host*
Conference Welcome. *J. P. Smith, I-ELCAP Advisory Board*
Program Overview. *C. Henschke*
I-ELCAP and IELCART Update. *C. Henschke*
- 9:30 – 11:00 **Global Updates of Screening Initiatives.** Moderator: *C. Connery*
9:30 – 9:45 A High Risk Lung Cancer Screening Program: The Canadian Way. *H. Schmidt*
9:45 – 10:00 Initiatives in China. *W. Tang*
10:00 – 10:15 Poland and Eastern Europe. *W. Rzyman*
10:15 – 10:30 European Position Statement and Implementation. *J. Field*
10:30 – 10:45 Screening in Brazil. *R. Sales dos Santos*
10:45 – 11:00 IASLC Lung Cancer Screening Initiative. *J. Mulshine*
- 11:00 – 11:15 *COFFEE BREAK*
- 11:15– 12:30 **Stage I Lung Cancer.** Moderator: *F. Grannis*
11:15 – 11:30 Surgical morbidity and mortality for Stage I lung cancer in CALGB. *N. Altorki*
11:30 – 11:45 Surgical morbidity and mortality in Stage I lung cancer in IELCART. *D. Nicastri*
11:45 – 12:00 Radiotherapy for Stage I. *K. Rosenzweig*
12:00 – 12:15 Sentinel lymph nodes in Stage I. *S. Quadri*
12:15 – 12:30 Tumor microenvironment and prognoses. *H. Pass*
- 12:30 – 1:30 *LUNCH*
- 1:30 – 2:30 **Preliminary findings from IELCART.** Moderator: *H. Pass*
1:30 – 1:45 Why the robot? *C. Connery*
1:45 – 2:00 Why not? *R. Flores*
2:00 – 2:15 What drives decisions in IELCART. *R. Yip*
2:15 – 2:30 Role of FNA in IELCART. *D. Yankelevitz*
- 2:30 – 3:30 **Aggressiveness of Stage I Lung Cancer** Moderator: *D. Yankelevitz*
2:30 – 2:45 Size, grade, histology: what do we know? *E. Burks*
2:45 – 3:00 Neoadjuvant therapy in early stage NSCLC. *F. Hirsch*
3:00 – 3:15 Tumor doubling times, PET scans and prognosis. *Y. Wang, M. Siddique*
3:15 – 3:30 Molecular characterization and prognosis. *L. Montuenga*

Tuesday, October 16th (continued)

- 3:30 – 4:00 *COFFEE BREAK*
- 4:00 – 4:45 **Panel Discussion of Difficult Cases.** Moderator: *T. Collins*
Panel members: *H. Suseelan, L. DiFabrizio, R. Flores, C. Connery, D. Yankelevitz,*
- 4:45 – 5:30 **Closed Meeting for I-ELCAP and IELCART Members**
- 6:00 – 9:00 **CONFERENCE DINNER – *American Bounty* at the Culinary Institute of America**

Wednesday, October 17th

- 8:00 *REGISTRATION & BUFFET BREAKFAST*
- 8:30 – 9:45 **Screening updates.** Moderator: *J. Mulshine*
8:30 – 8:45 Quantitative Screening Report. *A. Reeves*
8:45 – 9:00 Why are we not performing more screening? *A. McKee*
9:00 – 9:15 Nodule growth? *A. Jirapatnakul*
9:15 – 9:30 Low-dose radiation. *R. Subramaniam*
9:30 – 9:45 Efficiency of ACR-LungRADS and I-ELCAP. *C. Henschke*
- 9:45 – 10:00 *COFFEE BREAK*
- 10:00 – 11:00 **New Horizons.** Moderator: *J. Mulshine*
10:00 – 10:15 Where will improved image quality take us? *R. Avila*
10:15 – 10:30 Lessons learned from social media. *V. Krishnamurthy*
10:30 – 10:45 Using AI for outreach to smokers. *A. Ramos*
10:45 – 11:00 AI applications in medicine *A. McGrath*
- 11:00 – 12:00 **Heart Disease and CT screening.** Moderator: *K. Haleem*
11:00 – 11:15 Does heart size matter and how to measure it? *J. Ling*
11:15 – 11:30 Coronary artery disease in high-performance athletes. *K. Haleem*
11:30 – 11:45 Coronary contrast CT approaches. *M. Yen*
11:45 – 12:00 Aortic aneurysms and monitoring. *A. Messina*
- 12:00 – 12:45 *LUNCH*
- 12:45 – 1:45 **Health Check.** Moderator: *D. Yankelevitz*
12:45 – 1:00 Coverage and policy landscape. *A. McGlothin*
1:00 – 1:15 Population Health Metrics for LC Screening *B. Pyenson*
1:15 – 1:30 Implications of aortic valve calcifications. *Y. Zhu*
1:30 – 1:45 Reporting ancillary findings and legal considerations. *L. Goldsmith*
- 1:45 – 2:45 **Update on VA-PALS.** Moderator: *C. Henschke*
1:45 – 2:00 Update on VA-PALS and VALOR. *D. Moghanaki*
2:00 – 2:15 Implementation at the Phoenix VA. *S. Aguayo*
2:15 – 2:30 Development of VA QA for screening. *D. Yankelevitz*
2:30 – 2:45 Implementation Assessment. *J. Lewis, L. Spalluto*
- 2:45 – 3:30 **Interstitial Lung Disease.** Moderator: *T. Collins*
2:45 – 3:00 ILD in the community setting. *H. Suseelan*
3:00 – 3:15 Meta-analysis of ILD and lung cancer. *M. Salvatore*
3:15 – 3:30 Next generation treatments for ILD and monitoring them. *M. Padilla*